前往化源商城

17618-53-0 靶点实验数据

HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ICCB-Longwood/NSRB Screening Facility, Harvard Medical School 靶标:HCMV UL50
External ID: HMS1262
Protocol: NEC is stored at -80 degrees at a concentration of 15mg/ml in single use aliquots.

On the day of the screen, 20ul of purified NEC is aliquoted using a Multidrop Combi reagent dispenser into 384 well plates (Corning 3824). 100nl of compound dissolved in DMSO was transferred to each well of the assay plated via pin transfer. The plates (NEC + compound) are incubated at room temperature for 3 hours. Acceptor and donor reagents (CisBio 620/665 pair) are combined then added to each well at 5 microL volumes at a concentration of 8 nM and 80nM respectively. The plates are spun at 1k rpm for 1 min and incubated overnight at 4 degrees, then for one hour the subsequent day at room temperature.

Flourescent measurements are read on the Envision 1 plate reader at ICCB-L. The raw data consists of two fluorescence readings - at 665 nm and 620 nm for the acceptor and donor respectively.
Comment: Data analysis:
The raw data consists of two fluorescence readings - at 665 and 620 nm for the acceptor and donor respectively. The data is processed as a ratio of the emission from the acceptor over the donor (homogeneous time resolved fluorescence ratio). Normalized percent inhibition (NPI) for all experimental wells is calculated based on plate averages for negative and positive control HTRF ratio. Positives are scored as any ratio with a 50% or greater inhibition as compared with the positive control (i.e. NEC + Untagged UL50). To be considered a hit, both replicates need to score as positive. Activity scores are derived from NPI, with 100 = 100% inhibition (> 100% set to 100) and 0 = no inhibition (< 0% set to 0). Note that some compounds with NPI <50% (activity scores < 50) are classified as potential hits based on additional criteria (typically by selecting wells with low ratios compared to other experimental wells on the plate).
HTRF-Ratio_Avg.NPIHTRF-Ch1_AHTRF-Ch2_AHTRF-Ratio_AHTRF-Ch1_BHTRF-Ch2_BHTRF-Ratio_BHTRF-Ratio_Avg
2.3176387444236941789570632533624515
4.8173477312237241725770712440524064.5
4.2178687517237701815873952455424162
17.3118447012168911320463922065718774
6.6122586577186381432165022202620332
18.1115616789170291351266662027018649.5
-3.9111135694195171195949422419921858
10.3122156757180781398865062150019789
-20.7104254592227031187645852590224302.5
14.4123566766182621385868882011919190.5
5.8128686545196611401766002123820449.5
15.8122056703182081347068181975718982.5
3.2117425785202971292760542135320825
10.3122416415190821349065872048019781
-2.3109485353204521253054992278621619
9.1126446696188831392066202102719955
8.7134437082189821445368632105920020.5
-27100444376229521140941492749825225
10115506340182181327961962143219825
3.7107655590192581246756062223920748.5
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: LDHA
Protocol: The assay was optimized to 1536-well plates. Briefly, 3 muL of human lactate dehydrogenase 5 (#A38558H, Meridian Life Science, Inc., Memphis, TN) in LDH assay buffer (200 mM Tris HCl pH 7.4, 100 microM EDTA and 0.01% Tween-20) was added to a black solid bottom 1536-well assay plate (Greiner Bio-One) using a BioRAPTR FRD dispenser (Beckman Coulter, Brea, CA). A 1536-well pintool dispenser outfitted with 20 nL pins (Wako Automation, San Diego, CA) was used to transfer 23 nL of DMSO-solubilized compound (both library and vehicle controls) to each 1536-well assay plate. Following compound transfer, 1 muL of substrate solution containing NADH and sodium pyruvate (Sigma-Aldrich, St. Louis, MO) in LDH assay buffer was dispensed via BioRAPTR FRD to initiate the reaction. Final concentrations in the 4 microL reaction volume were 2 nM LDHA enzyme, 0.06 mM NADH and 0.2 mM sodium pyruvate. Following a 5 minute incubation period at room temperature, 1 muL of detection reagent (C. kluyveri diaphorase (Sigma-Aldrich) and resazurin sodium salt (Sigma-Aldrich) in LDH assay buffer) was added to a total volume of 5 muL. Final concentrations of detection reagents were 0.133 mg/mL diaphorase and 37 muM resazurin. Plates were immediately transferred to a ViewLux microplate imager (PerkinElmer, Waltham, MA), and any resulting resorufin fluorescence was measured (ex540, em590 nm) at 0 and 20 minutes. Fluorescence was normalized using enzyme-free and DMSO-treated control wells on each plate.
Comment: PubChem score indicates % inhibition at 229 uM or 114 uM of the compound (Max_response). Active compounds with Max_response greater than -100%, PUBCHEM_ACTIVITY_SCORE is 100. Active compounds with Max_response between -80% and -100%, PUBCHEM_ACTIVITY_SCORE is 80. Active compounds with Max_response between -60% and -80%, PUBCHEM_ACTIVITY_SCORE is 60. Active compounds with Max_response between -30% and -60%, PUBCHEM_ACTIVITY_SCORE is 40. Inconclusive Compounds with Max_response between -25% and -30% have PUBCHEM_ACTIVITY_SCORE 20. For all inactive compounds with Max_response greater than -25%, PUBCHEM_ACTIVITY_SCORE is 0
Max_ResponseActivity at 2.29 uMActivity at 11.40 uMActivity at 57.10 uMActivity at 114.0 uMActivity at 229.0 uMCompound QC
-13.2744-14.0597-11.6112-13.2744QC'd by CBC
-13.2736-2.2436-1.4106-3.5076-4.2706-13.2736QC'd by ChemBridge
-13.2725-6.3492-3.253-0.0584-6.7999-13.2725QC'd by Enamine
-13.2721-2.684-6.1454-14.2744-13.2721-0.8973QC'd by InterBioScreen
-13.26881.98380.4889-13.2688QC'd by CBC
-13.2682-4.48462.9589-5.115-5.7595-13.2682QC'd by Sytravon
-13.2658-0.93-4.4888-3.7077-0.7595-13.2658QC'd by Scripps Research Institute Molecular Screening Center-Florida
-13.2621-10.0397-8.5786-8.5671-13.2621-10.4851QC'd by InterBioScreen
-13.2619-4.902-18.7355-13.2619QC'd by CBC
-13.2616-5.6993-9.4488-8.2485-1.1117-13.2616QC'd by Asinex Ltd.
-13.2589-2.6923-5.6679-1.3754-4.9233-13.2589QC'd by ChemBridge
-13.2586-7.6996-6.7417-9.0608-13.258613.0861QC'd by Chem Div
-13.2584.5885-10.8854-13.258QC'd by CBC
-13.2566-1.7741-2.7236-3.5771-3.8709-13.2566QC'd by Chem Div
-13.255-2.1061.9951-5.3796-7.5294-13.255QC'd by Sytravon
-13.2542-3.8713-0.3776-5.8085-5.7762-13.2542QC'd by Sytravon
-13.2537-9.0401-8.2673-9.7055-13.2537QC'd by ChemBridge
-13.2524-8.3625-5.9151-4.3599-2.4204-13.2524QC'd by Life Chemicals
-13.2524-11.5667-8.9808-13.1831-13.2524-13.0056QC'd by Enamine
-13.252412.60356.6367-13.2524QC'd by CBC
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: stopgo-p2-SytraCBC-dual-FF
Protocol: Reagents:
StopGo2A HEK-NPG-Luc cells and other necessary media and controls were provided by Dr. Atkins's lab. Compound PTC124 was used as a control. Dose response was assessed using a 1:2 dilution of control compound, with the top dose of 50uM final concentration. Background signal was normalized to wells treated with DMSO only.

Assay Protocol:
In brief, four microliters (2400 cells/well) of StopGo2A HEK-NPG-Luc cells were plated and incubated overnight at 37C. Twenty-three nanoliters of compounds and control were added to the wells using a 1536 array Kalypsys pintool workstation. After an over night incubation (at 37C) with compounds / control, 2.5 uL of Dual/Glo Firefly reagent was added. Firefly luciferase signal was obtained using the PerkinElmer ViewLux plate reader after 20min of room temperature incubation. Dual/Glo Renilla Lucifrase reagents were then added followed by additional 20 min room temperature incubation. Finally, the renilla luciferase signal was obtained using the PerkinElmer ViewLux reader.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00460 uMActivity at 0.023 uMActivity at 0.046 uMActivity at 0.112 uMActivity at 0.230 uMActivity at 0.460 uMActivity at 0.871 uMActivity at 0.984 uMActivity at 1.439 uMActivity at 2.300 uMActivity at 4.560 uMActivity at 5.230 uMActivity at 7.193 uMActivity at 11.50 uMActivity at 22.87 uMActivity at 26.96 uMActivity at 44.22 uMActivity at 57.50 uMActivity at 114.7 uMActivity at 121.0 uMCompound QC
Inactive0-6.84.95490.81592-8.87640 0 0 0-0.3922-6.984.92071.8774-0.3922QC'd by CBC
Inactive0-64.95490.99893-8.474340 0 0 1-8.9436-8.7286-0.74863.1076-8.9436QC'd by CBC
Inactive0-5.451.75290.999931.5-1.401840 0 0 10-1.16822.48627.83070QC'd by CBC
Inactive0-60.60.9574-3.55781840 0 0 0-2.964813.96745.37522.1822-2.9648QC'd by CBC
Activator0.891355.35450Complete curve; partial efficacy; poor fit-6.054.95490.996847.9876-7.36691.40 0 0 045.9161-7.516336.245149.430745.9161QC'd by CBC
Inactive04-0.40613.15817.14891.8466-0.4061QC'd by CBC
Inactive048.02199.75862.63914.5158.0219QC'd by CBC
Inactive0-4.72.90230.933614-3.767840 0 0 013.2222-6.4732-1.1472-0.694213.2222QC'd by CBC
Inactive0-6.754.95490.62345.5-2.856340 0 0 1-0.8656-1.96369.1142.2001-0.8656QC'd by CBC
Activator3.1623120.58050Partial curve; high efficacy; poor fit-5.52.58841125.84165.26112.30 0 0 1-13.87585.026113.541121.9395-13.8758QC'd by CBC
Inactive0-5.054.0950.99539.916310.540 0 0 039.90711.81019.210332.148439.907QC'd by CBC
Inactive0-6.754.95490.68855.5-14.272340 0 0 0-1.4364-12.310313.15054.6329-1.4364QC'd by CBC
Inactive0-6.84.95490.48777-4.29940 0 0 012.0135-2.33258.02360.561112.0135QC'd by CBC
Activator14.125456.99660Partial curve; partial efficacy; poor fit-4.851.55790.997555.2294-1.76712.40 0 0 049.6994-2.53631.145221.508449.6994QC'd by CBC
Inactive0-6.74.95490.69788.5-0.540 0 0 10.95120.101311.40645.14890.9512QC'd by CBC
Inactive0-6.84.95490.67113-7.754240 0 0 10-4.378520.24456.04850QC'd by CBC
Inactive04-3.0754-7.5861-4.61-0.5732-3.0754QC'd by CBC
Inactive0-4.950.70.969-220.540 0 0 02.43720.237815.432810.70092.437QC'd by CBC
Inactive0-6.84.50450.7622-2-15.31340 0 0 0-4.8971-12.76082.2051-3.2116-4.8971QC'd by CBC
Inactive0-6.054.50450.999713-6.546540 0 0 10-6.28888.282512.94060QC'd by CBC
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ICCB-Longwood/NSRB Screening Facility, Harvard Medical School 靶标:
External ID: HMS1303
Protocol: Prior to screening, lyophilized FITC-GIV peptide (a.a. 1671-1701) is dissolved in 100% DMSO to a concentration of 0.5 mM, then further diluted with water to a final concentration of 50 microM. One stock was prepared in batch for the entire screen and aliquoted. All protein stocks were stored at -80C. Thawing of aliquots on the day of the assay was performed rapidly at room temperature.

Prior to transfer of screening compounds, experimental wells of 384-well assay plates were pre-filled with 37.8 nM of FITC-GIV peptide (for 25 nM final concentration) in a 10 microL volume of assay buffer (50 mM Tris [pH 7.4], 100 mM NaCl, 10 mM MgCl2, 5 mM EDTA, 0.4% NP-40, 30 microM GDP, 1 mM DTT). Control wells were pre-filled with 37.8 nM of FITC-GIV peptide in 10 microL of assay buffer containing either 1% DMSO (vehicle negative control) or 45.3 microM AlCl3+15.1 mM NaF (AlF4- positive control). Each plate contained 16 negative control and 16 positive control wells. Plates were centrifuged at 1000xg for 2 minutes to eliminate bubbling on the surface. Following, 100 nL of experimental compound was pin-transferred into individual wells for each of two replicate assay plates (A&B). After pin-transfer, 5 microL of 3 microM His-tagged rat Galphai3 purified from E. coli (for 1 microM final concentration) was added to each well, and assay plates were shaken at low speed for 5 seconds. Final assay volume was 15 microL. Plates were centrifuged at 1000xg for 2 minutes to eliminate bubbling on the surface and shaken for 10 seconds prior to an incubation of 90 minutes at room temperature. Plates were protected from prolonged light exposure. All manipulations were performed at room temperature.

Assay plates were read with a PerkinElmer Wallac EnVision Multilabel 2103 plate reader using the fluorescent polarization measurement technology with a D505fp/D535 dual mirror and a 480 nm excitation filter. 535 nm emission filters were used for P and S channel reads at 11 mm measurement height with 30 flashes and detector gains of 319 and 563. G-factor 0.96.

Negative control: DMSO
Positive control: Aluminum tetrafluoride (AlF4-, composite of NaF and AlCl3)
Comment: Calculated result values and scoring of active compounds:

Z-score: Indicates the number of standard deviations an experimental condition is from the mean. It is calculated based on plate average (u) and standard deviation (s) of experimental well fluorescence polarization (FP) measurements for each replicate. Z-score (z) is defined as the quotient of the mean of the experimental well population subtracted from an individual well's FP (x), divided by the standard deviation within the experimental wells; z = (x-u)/s.

Normalized percent control: calculated by subtracting plate average positive control FP from experimental well FP, dividing by the difference between plate average negative and positive control FP, and multiplying by 100.

STD: the number of standard deviations from the plate average negative control FP for each replicate experimental well

Compound wells with FP values exceeding +5 standard deviations from the negative control sample average were flagged as potential aggregators or fluorescence quenchers due to their high polarization signal (HighPol) and were excluded from further consideration. Activity scores were calculated by averaging the replicate normalized percent of control values and subtracting from 100 (score based on single replicate if data for other replicate was excluded for any reason). Result values < 0 were set to 0 (no activity) and > 100 were set to 100 (100% activity). Compounds with activity score >= 15 were considered active.
mP_AFluorTotal_APchan_ASchan_AmP_BFluorTotal_BPchan_BSchan_BZ-score_AZ-score_BPercent Ctrl_APercent Ctrl_BSTD_ASTD_BNote: Polarization Artifact
122.41957988860658427448204128.11963767260572207523232-1.18225-0.63523293.2647101.541-1.80030.362745
124.61958252660565717469384129.81962517560450197535137-0.634716-0.19961197.3807104.669-0.7001171.09906
124.21966389660838267496244126.21969903460848867529262-0.734268-1.122196.632498.0451-0.90015-0.460198
1231973179861103407511118126.71971411360873537539407-1.03292-0.99397994.387398.965-1.50025-0.243634
128.11989636061370667622228130.519724618607261775793840.236366-0.0202377103.929105.9571.050181.40225
125.61986771661402087587300131.31967349360531227567249-0.3858350.1847699.2516107.429-0.2000331.74875
127.72002396861782517667466128.819866494612424676180020.136814-0.455859103.181102.8290.8501420.665934
129.21961772360456307526463132.719789155608172076257150.5101340.543507105.987110.0051.600272.35513
130.91974707560775087592059133.819696771604822176003290.9332310.82538109.167112.0292.450412.83157
127.41995714661589967639154131.119907155612592276553110.06214940.133511102.619107.0610.7001171.66213
128.61970436060754757553410127.919896451613799676204590.360806-0.686482104.864101.1731.300220.276119
126.51975466161009937552675131.21981143860959967619446-0.1618430.159136100.935107.2450.2500421.70544
125.21989803761513307595377128.51982052261116137597296-0.485388-0.53273398.5033102.277-0.4000670.535996
125.21974444761039237536601130.11961319460400397533116-0.485388-0.12273798.5033105.221-0.4000671.229
127.41996280061609707640860131.319894559612117976522010.06214940.18476102.619107.4290.7001171.74875
128.82002040261715807677242132.519888130611339976613320.4105820.492258105.239109.6371.400232.26851
128.31997122561589057653415131.820071564617330377249580.2861420.312884104.303108.3491.150191.96532
128.7197498216088940757194112919670633606278775450590.385694-0.404609105.051103.1971.350230.752559
125.719727542609617775351881291962415560487067526743-0.360947-0.40460999.4387103.197-0.1500250.752559
127.82004995261859487678056130.820021937616251676969050.1617020.0566366103.368106.5090.900151.53219
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ICCB-Longwood/NSRB Screening Facility, Harvard Medical School 靶标:
External ID: HMS979
Protocol: Cation-adjusted Mueller Hinton II broth supplemented with 0.005% Tween-80 was inoculated with a single colony of S. aureus RN4220. Following overnight incubation, the culture was diluted 1:100 into fresh medium, and incubation was continued until the bacterial suspension reached an optical density at 600 nm (OD600) of 0.6, corresponding to a bacterial density of 5 x 10E8 colony forming units (CFU)/mL. An aliquot of this culture was diluted 1:400 with fresh medium and stored on ice until use. Assay plates were prepared for compound transfer in quadruplicate to enable screening of compounds at two temperatures in duplicate. The plate layout was as follows: wells in columns 1-22 were loaded with culture medium at 25 microL/well; wells in column 23 contained the screening negative control (medium only); wells in column 24 contained the screening positive control (medium containing 25 microg/mL chloramphenicol). 300 nL of experimental compounds were transferred by stainless steel pin array from library plate to assay plates.

25 microL of the bacterial suspension was added to each assay well. Assay plates were incubated at 42 degrees C in humidified chambers (humidity > 85%). After 20 h, the OD600 was measured using a plate reader in absorbance mode.
Comment: Data analysis description:

Absorbance values at 42 degrees C and 30 degrees C for each replicate were normalized to positive and negative control plate average absorbance, and replicate normalized values were averaged to calculate an average relative absorbance at both temperatures. A substance was considered a temperature-dependent positive at 42 degrees C if average relative absorbance <= 50 and the difference between relative absorbance at 30 degrees C and 42 degrees C >= 20 (relative absorbance 30 degrees C - relative absorbance 42 degrees C >= 20). A substance was considered a temperature-independent positive if relative absorbance at both 30 degrees C and 42 degrees C < 10.

Activity scores were calculated using average relative absorbance at both temperatures. Average relative absorbance <= 0 was scored as 100 for activity; average relative absorbance >= 100 was scored as 0 for activityy. Average relative absorbance between 0 and 100 was subtracted from 100 to generate activity scores for intermediate values (i.e. average relative absorbance = 40 corresponds to an activity score of 60).

Note that since this is treated as a panel assay, the query for active compounds includes many that were considered active at both temperatures. The final Pubchem activity score is the activity score at 42 degrees C, and compounds scored as active (PUBCHEM_ACTIVITY_OUTCOME = 2) include both temperature-dependent and temperature-independent active substances.
Absorbance_42C_AAbsorbance_42C_BRel_Abs_42C_ARel_Abs_42C_BAvg_Rel_Abs_42CAbsorbance_30C_AAbsorbance_30C_BRel_Abs_30C_ARel_Abs_30C_BAvg_Rel_Abs_30C(Abs_30C)-(Abs_42C)Activity Score_30CActivity Outcome_TempDepActivity Outcome_TempIndActivity Type
0.3580.40898.28110.75104.520.6440.645107.98104.06106.021.50II
0.350.38695.78104.1199.950.6470.643108.52103.71106.126.170II
0.370.401102.03108.64105.330.6160.645102.96104.06103.51-1.830II
0.3660.403100.78109.24105.010.6140.578102.692.4997.55-7.472II
0.3670.387101.09104.41102.750.5790.62396.32100.2698.29-4.462II
0.350.38395.78103.2199.50.690.616116.2499.05107.648.150II
0.3610.36899.2298.6898.950.6020.583100.4593.3596.9-2.053II
0.3390.39592.35106.8399.590.5780.64896.14104.58100.360.770II
0.3630.35299.8493.8596.850.5840.60197.2296.4696.84-0.013II
0.360.35898.9195.6697.280.6670.616112.1199.05105.588.30II
0.2340.37659.56101.0980.330.590.6598.3104.92101.6121.280II
0.3640.214100.1652.276.180.6090.564101.790.0795.8919.714II
0.3770.396104.22107.13105.670.6790.618114.2699.4106.831.160II
0.3470.35794.8595.3695.10.620.648103.68104.58104.139.020II
0.3590.38198.59102.6100.60.5890.6198.1298.0198.07-2.532II
0.3570.39297.97105.92101.950.4890.49780.1778.579.34-22.6121II
0.3690.361101.7296.5799.140.5910.66698.47107.68103.083.940II
0.4960.531141.37147.88144.630.6150.661102.78106.82104.8-39.830II
0.390.466108.27128.26118.270.4130.58566.5493.780.12-38.1520II
0.3670.425101.09115.88108.490.5340.54388.2586.4587.35-21.1413II
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: stopgo-p2-SytraCBC-dual-Ren
Protocol: Reagents:
StopGo2A HEK-NPG-Luc cells and other necessary media and controls were provided by Dr. Atkins's lab. Compound PTC124 was used as a control. Dose response was assessed using a 1:2 dilution of control compound, with the top dose of 50uM final concentration. Background signal was normalized to wells treated with DMSO only.

Assay Protocol:
In brief, four microliters (2400 cells/well) of StopGo2A HEK-NPG-Luc cells were plated and incubated overnight at 37C. Twenty-three nanoliters of compounds and control were added to the wells using a 1536 array Kalypsys pintool workstation. After an overnight incubation (at 37C) with compounds / control, 2.5 uL of Dual/Glo Firefly reagent was added. Firefly luciferase signal was obtained using the PerkinElmer ViewLux plate reader after 20min of room temperature incubation. Dual/Glo Renilla Lucifrase reagents were then added followed by additional 20 min room temperature incubation. Finally, the renilla luciferase signal was obtained using the PerkinElmer ViewLux reader.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00460 uMActivity at 0.023 uMActivity at 0.046 uMActivity at 0.092 uMActivity at 0.115 uMActivity at 0.230 uMActivity at 0.460 uMActivity at 0.911 uMActivity at 1.057 uMActivity at 1.771 uMActivity at 2.301 uMActivity at 4.634 uMActivity at 5.773 uMActivity at 11.50 uMActivity at 16.40 uMActivity at 23.82 uMActivity at 35.99 uMActivity at 57.50 uMActivity at 114.4 uMActivity at 129.1 uMActivity at 273.4 uMActivity at 288.0 uMCompound QC
Activator15.848972.76670Partial curve; partial efficacy; poor fit-4.810.995671.5604-1.20632.40 0 0 056.9219-2.70325.718429.072156.9219QC'd by CBC
Inactive0-5.652.72020.876-3.076-11.137840 0 0 0-4.8556-10.9482-10.07-0.8967-4.8556QC'd by CBC
Activator14.1254116.35980Partial curve; high efficacy; poor fit-4.852.25260.9976114.9836-1.37612.30 0 0 0110.7742-4.01652.526342.9951110.7742QC'd by CBC
Inactive0-4.354.95490.62039-2.125740 0 0 06.649-3.82222.8199-4.68816.649QC'd by CBC
Activator22.387269.80210Partial curve; partial efficacy-4.651.75290.99966.6142-3.18792.20 0 0 055.5041-3.9302-1.545313.513455.5041QC'd by CBC
Inactive04-10.8628-6.0946-6.3923-2.7723-10.8628QC'd by CBC
Activator3.162346.56160Complete curve; partial efficacy-5.51140.0835-6.47811.20 0 0 037.587-4.78416.055430.206537.587QC'd by CBC
Inactive04-5.1322-4.7917-1.3649-10.6528-5.1322QC'd by CBC
Inactive0-4.44.44950.7339130.999240 0 0 011.2209-2.50075.02590.301511.2209QC'd by CBC
Inactive0411.75236.54273.70753.760211.7523QC'd by CBC
Inactive04-13.953-10.1902-10-18.4577-13.953QC'd by CBC
Inactive04-4.5083-2.06295.4547-1.4612-4.5083QC'd by CBC
Inactive04-7.5306-15.4441-6.4413-15.0974-7.5306QC'd by CBC
Inactive0-4.652.25260.9477-26.3385-15.893440 0 0 0-25.2821-17.3753-14.9112-17.8522-25.2821QC'd by CBC
Inactive04-12.6647-11.4457-10.7961-20.5075-12.6647QC'd by CBC
Inactive0-5.14.95490.594-16.1597-5.606740 0 0 1-3.9011-10.3012-3.0056-14.7164-3.9011QC'd by CBC
Inactive0-5.154.95490.9234-15.5602-3.948840 0 0 1-5.8836-5.9172-2.4573-14.6335-5.8836QC'd by CBC
Inactive0-4.354.44950.7251-13.3612-240 0 0 0-10.7177-1.1966-5.59780.8791-10.7177QC'd by CBC
Inactive0-5.74.50450.80751.010810.540 0 0 04.435110.69059.7726-1.65774.4351QC'd by CBC
Activator35.481330.78070Partial curve; partial efficacy; poor fit-4.451.47810.970347.280716.52.40 0 0 037.296914.420618.816221.266337.2969QC'd by CBC